{"id":15210,"date":"2022-05-20T05:00:58","date_gmt":"2022-05-20T09:00:58","guid":{"rendered":"https:\/\/www.policymed.com\/?p=15210"},"modified":"2022-05-19T22:34:03","modified_gmt":"2022-05-20T02:34:03","slug":"policy-and-medicine-compliance-update-sun-pharma-anti-trust-settlement-and-indepth-coverage-of-state-opioid-actions","status":"publish","type":"post","link":"https:\/\/www.policymed.com\/2022\/05\/policy-and-medicine-compliance-update-sun-pharma-anti-trust-settlement-and-indepth-coverage-of-state-opioid-actions.html","title":{"rendered":"Policy and Medicine Compliance Update — Sun Pharma Anti Trust Settlement and Indepth Coverage of State Opioid Actions"},"content":{"rendered":"<p><a href=\"https:\/\/complianceupdate.policymed.com\/\">Policy and Medicine Compliance Update<\/a>\u00a0is our monthly compliance publication designed to help compliance professionals go in depth in issues and stay up to date on the latest trends.\u00a0 \u00a0We encourage you to\u00a0<a href=\"https:\/\/pmcu2020.policymed.com\/checkout\/?rid=m0974S\">subscribe<\/a>\u00a0to our monthly publication\u00a0<a href=\"https:\/\/complianceupdate.policymed.com\/\"><em>Policy and Medicine Compliance Update<\/em><\/a>.<\/p>\n<p>We begin our May issue with a review of the recent Sun Pharma settlement in the long-running Ranbaxy antitrust litigation.\u00a0 Although part of the wider enforcement actions against generic manufacturers for alleged anti-competitive behavior, this case focused on the misuse of the FDA\u2019s ANDA process to block competitors.<\/p>\n<p>Turning to litigation and enforcement, we cover three new developments in the ongoing opioid litigation.\u00a0 However, these three cases have wider implications for life science legal and compliance beyond the narrow scope of opioids.<\/p>\n<p>First, we examine a case involving two physicians charged with running an alleged \u201cpill mill\u201d in Alabama.\u00a0 Although set in the context of prescription opioids, the case involves the good faith prescribing of pharmaceuticals and is now before the U.S. Supreme Court, which heard oral arguments in March.<\/p>\n<p>Next, we examine the latest developments in Endo\u2019s ongoing discovery woes in Tennessee.\u00a0 \u00a0In another state action, the court entered a default judgment against Endo on the question of liability only to have that judgment vacated and the judge disqualified.<\/p>\n<p>Finally, we explore the latest settlement between J&J and West Virginia and its potential implications.\u00a0 In a marked departure from its previous litigation strategy in Oklahoma, J&J ultimately chose to settle rather than risk a jury verdict.\u00a0 The case also highlights the challenges of a corporate parent company avoiding liability for action of its subsidiaries when the parent exercises substantial control over the activities of the subsidiary.<\/p>\n<h6>Articles<\/h6>\n<h5>FEATURE<\/h5>\n<h1><a href=\"https:\/\/complianceupdate.policymed.com\/\">Antitrust, FDA & Sun Pharma \u2013 The End of the Line<\/a><\/h1>\n<h2><em>A Consumer Protection Win & Signal to Generic Drug Manufacturers<\/em><\/h2>\n<p>By Robert N. Wilkey, Esq., Senior Staff Writer<\/p>\n<p><strong>Summary:<\/strong> In March 2022, Sun Pharma announced a settlement in the long-running Ranbaxy antitrust litigation.\u00a0 The settlement is a stern warning and reminder to life sciences companies of the substantial risks and costs associated with business efforts to usurp antitrust and generic competition within the industry.\u00a0\u00a0 It also sends a message to outside lawyers and consultants that work with industry clients.<\/p>\n<h5>Litigation & Enforcement<\/h5>\n<h1><a href=\"https:\/\/complianceupdate.policymed.com\/\">Alabama Pill Mill Case Gets to the U.S. Supreme Court<\/a><\/h1>\n<h2><em>Does a \u201cGood Faith\u201d Defense Still Exist for Controlled Substances?<\/em><\/h2>\n<p>By Robert N. Wilkey, Esq., Senior Staff Writer<\/p>\n<p><strong>Summary:<\/strong> In 2017, two physicians were sentenced to at least 20 years imprisonment for allegedly operating a \u201cpill mill\u201d in Alabama.\u00a0 In March 2022, the U.S. Supreme Court heard oral arguments on what constitutes \u201cgood faith\u201d and acting in accordance with proper medical practice.\u00a0\u00a0 The case has broad implications for prescribing controlled substances and for individual physician accountability.<\/p>\n<h1><a href=\"https:\/\/complianceupdate.policymed.com\/\">Litigation Shenanigans<\/a><\/h1>\n<h2><em>Endo\u2019s Opioid Discovery Defiance Results in New Sanctions <\/em><\/h2>\n<p>By Kirt Kraeuter, Staff Writer<\/p>\n<p><strong>Summary:<\/strong> Even though Endo\u2019s second default judgment in the face of its repeated failures to comply with opioid discovery requests was vacated, it demonstrates the importance of proper discovery.\u00a0 This article explores the latest rulings as well as the implications for other cases in the face of the cross-notice obligations imposed by the U.S. District Court overseeing the federal opioid multi-district litigation.<\/p>\n<h1><a href=\"https:\/\/complianceupdate.policymed.com\/\">Just Another Settlement or Something More<\/a><\/h1>\n<p><em>Examining J&J\u2019s West Virginia Opioid Settlement<\/em><\/p>\n<p>By Robert N. Wilkey, Esq., Senior Staff Writer<\/p>\n<p><strong>Summary: <\/strong>In April 2022, J&J publicly announced a $99 million settlement with the State of West Virginia to settle allegations that it helped fuel an opioid addiction crisis within the state.\u00a0 The settlement may signal a change of heart and a renewed propensity by at least J&J to resolve opioid claims without a jury trial.<\/p>\n<p>From all of us here (virtually) at\u00a0<a href=\"https:\/\/complianceupdate.policymed.com\/\"><em>Policy & Medicine Compliance Update<\/em><\/a>, we hope all our readers and their families are safe and healthy during these challenging times.\u00a0 \u00a0We\u00a0<a href=\"https:\/\/pmcu2020.policymed.com\/checkout\/?rid=m0974S\">encourage you to subscribe<\/a>\u00a0 and for your continuing support making us the most comprehensive, up-to-date compliance publication for life science compliance professionals.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Policy and Medicine Compliance Update\u00a0is our monthly compliance publication designed to help compliance professionals go in depth in issues and stay up to date on the latest trends.\u00a0 \u00a0We encourage you to\u00a0subscribe\u00a0to our monthly publication\u00a0Policy and Medicine Compliance Update. We begin our May issue with a review of the recent Sun Pharma settlement in the […]<\/p>\n","protected":false},"author":1,"featured_media":15211,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29,45,8,24],"tags":[1101],"class_list":["post-15210","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance","category-medical-legal","category-opioids","category-state-policy","tag-new"],"_links":{"self":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/15210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/comments?post=15210"}],"version-history":[{"count":1,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/15210\/revisions"}],"predecessor-version":[{"id":15212,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/15210\/revisions\/15212"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/media\/15211"}],"wp:attachment":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/media?parent=15210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/categories?post=15210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/tags?post=15210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}